Jump to ContentJump to Main Navigation

Online

249,00 € / $374.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
June 2005
ISSN:
1437-4331
DOI:
10.1515/CCLM.2003.229

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 249.00
RRP for USA, Canada, Mexico
US$ 374.00 *
Print
Individual Subscription Online only
Euro [D] 1577.00
RRP for USA, Canada, Mexico
US$ 2365.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1893.00
RRP for USA, Canada, Mexico
US$ 2838.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the International Federation of Clinical Chemistry and Laboratory Medicine and the European Federation of Clinical Chemistry and Laboratory Medicine

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Lippi, Giuseppe / Gillery, Philippe / Kazmierczak, Steven / Lackner, Karl J. / Melichar, Bohuslav / Siest, Gérard / Whitfield, John B. / Abi Fadel, Marianne / Alvarez Menendez, Francisco V. / Azzazy, Hassan M.E. / Diamandis, Eleftherios P. / Eckardstein, Arnold / Favaloro, Emmanuel J. / Griesmacher, Andrea / Herrmann, Wolfgang / Hoffmann, Johannes J.M.L. / Hooijkaas, Herbert / Ichihara, Kiyoshi / Kaabachi, Naziha / Kim, Jeong-Ho / Korte, Wolfgang / Kroupis, Christos / Lai, Leslie Charles / Lam, Wai Kei Christopher / Marc, Janja / Miyoshi, Eiji / Özben, Tomris / Palicka, Vladimir / Panteghini, Mauro / Queralto, Jose M. / Scartezini, Marileia / Simundic, Ana-Maria / Tsongalis, Gregory J. / Wallemacq, Pierre E. / Yan, Shengkai / Young, Ian S. / Chiu, Rossa Wai Kwun / Ghosh, Debabrata / Kappelmayer, Janos / Lehmann, Sylvain / Sypniewska, Grazyna

12 Issues per year

Increased IMPACT FACTOR 2011: 2.150
Rank 10 out of 32 in category Medical Laboratory Technology in the 2011 Thomson Reuters Journal Citation Report/Science Edition

VolumeIssuePage

Issues

Hyperhomocysteinemia and B-Vitamin Status after Discontinuation of Oral Anticoagulation Therapy in Patients with a History of Venous Thromboembolism

Agata Sobczyńska-Malefora / Dominic J. Harrington / Savita Rangarajan / Jo-Anne Kovacs / Martin J. Shearer / Geoffrey F. Savidge

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 41, Issue 11, Pages 1493–1497, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2003.229, June 2005

Publication History:
Published Online:
2005-06-01

Abstract

Although hyperhomocysteinemia is an established risk factor for venous thromboembolism there is no consensus for routine determination of circulating homocysteine in the UK, either at the beginning or end of oral anticoagulation therapy. The purpose of this study was to evaluate the prevalence of hyperhomocysteinemia and its relationship to folate and vitamin B12 status in subjects with venous thromboembolism 4 weeks after discontinuation of warfarin therapy. In 78 consecutively recruited patients, plasma homocysteine was significantly higher (p < 0.001) and red cell folate significantly lower (p = 0.03) than in controls. Plasma vitamin B12 was similar in both groups. Strikingly, 38.5% of patients had hyperhomocysteinemia (>15 μmol/l). Retrospective analysis revealed a significant positive association between plasma total homocysteine and duration of warfarin therapy (p < 0.001) but a negative, though non-significant (p = 0.06), trend with warfarin dose. The results do not suggest any direct interaction between warfarin and plasma homocysteine but raise the possibility of reduced intake of a common food source of folate and vitamin K. One possibility is the shortage of green-leafy vegetables since patients are often advised to limit their intake of this major source of vitamin K. On the basis of this study we suggest that homocysteine screening should be carried out at the time that patients begin warfarin therapy.

Comments (0)

Please log in or register to comment.